Royalty Report: Drugs, Pharmaceuticals, Disease – Collection: 305270

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 10

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 10

Primary Industries

  • Drugs
  • Pharmaceuticals
  • Disease
  • Therapeutic
  • Delivery
  • Drug Discovery

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 305270

License Grant
Licensor granted to Canadian Licensee an exclusive sublicense in Canada for, among other things, the development and commercialization of Stendra® .
License Property
Stendra® is an FDA approved PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (“ED”). As a distinct molecule with high in-vitro affinity and selectivity for penile tissue (clinical significance of this in-vitro selectivity profile is unknown), Stendra® offers the erectile dysfunction therapeutic landscape a valuable addition as an oral ED therapy that may be taken as early as approximately 15 minutes prior to sexual engagement, with or without food when using the 100mg or 200mg dosing (does not apply to 50mg dosing).
Field of Use
The Field of Use is for the treatment of male erectile dysfunction.  Erectile Dysfunction is the inability to attain an erection when stimulated and the ability to maintain the erection to completion.

IPSCIO Record ID: 326906

License Grant
In connection with the consummation of the Mergers, the Party D (Licensee) assumed Party C’s rights and obligations that were sublicensed from Party B. The rights and obligations license is for the commercialization of Stendra®. The License Agreement gave Party C the right to sell avanafil in the U.S. and its territories, Canada, South America, and India from Party A (Licensor). This license is in consideration for the trademark assignment and the use of the trademarks associated with Stendra® and the Party B technology.
License Property
Stendra® is an FDA approved PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (“ED”) and is the only patent protected PDE-5 inhibitor on the market. As a distinct molecule with high in-vitro affinity and selectivity for penile tissue (clinical significance of this in-vitro selectivity profile is unknown), Stendra® offers the erectile dysfunction therapeutic landscape a valuable addition as an oral ED therapy that may be taken as early as approximately 15 minutes prior to sexual engagement, with or without food when using the 100mg or 200mg dosing (does not apply to 50mg dosing).
Field of Use
The Field of Use is for the treatment of male erectile dysfunction.

IPSCIO Record ID: 326966

License Grant
In connection with the consummation of the Mergers between Party C and Party D (Licensee), the Party D assumed Party C’s rights and obligations that were sublicensed from Party B (Licensor). The rights and obligations license is for the commercialization of Stendra®. The License Agreement gave Party C the right to sell avanafil in the U.S. and its territories, Canada, South America, and India.
License Property
Stendra® is an FDA approved PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (“ED”) and is the only patent protected PDE-5 inhibitor on the market. As a distinct molecule with high in-vitro affinity and selectivity for penile tissue (clinical significance of this in-vitro selectivity profile is unknown), Stendra® offers the erectile dysfunction therapeutic landscape a valuable addition as an oral ED therapy that may be taken as early as approximately 15 minutes prior to sexual engagement, with or without food when using the 100mg or 200mg dosing (does not apply to 50mg dosing).
Field of Use
The Field of Use is for the treatment of male erectile dysfunction.

IPSCIO Record ID: 306428

License Grant
Licensee purchased and received the license for the commercialization and exploitation of Stendra and acquired the current Stendra product and sample inventories as of September 30, 2016 that were owned by Party A.  In December 2000, Party A originally was granted the license from Licensor to develop, market, and manufacture Stendra.

The License Agreement gives Licensee the right to sell Stendra in the U.S and its territories, Canada, South America, and India. This also includes for the trademark assignment and the use of the trademarks associated with the Product and the Licensor technology.

License Property
Stendra® is a PDE5 inhibitor pharmaceutical product indicated for the treatment of male erectile dysfunction.  As a distinct molecule with high in-vitro affinity and selectivity for penile tissue (clinical significance of this in-vitro selectivity profile is unknown), Stendra® offers the erectile dysfunction therapeutic landscape a valuable addition as an oral ED therapy that may be taken as early as approximately 15 minutes prior to sexual engagement, with or without food when using the 100mg or 200mg dosing (does not apply to 50mg dosing).
Field of Use
The Field of Use is for the treatment of male erectile dysfunction.

IPSCIO Record ID: 383748

License Grant
Company granted to Licensee an exclusive sublicense in Canada for, among other things, the development and commercialization of Stendra® avanafil.
License Property
Stendra® is a PDE-5 inhibitor that offers the ED therapeutic landscape a valuable addition as an oral ED therapy that may be taken as early as approximately 15 minutes prior to sexual engagement, with or without food when using the 100mg or 200mg dosing (does not apply to 50mg dosing).
Field of Use
Field of use is for the treatment of male erectile dysfunction (ED).

IPSCIO Record ID: 305272

License Grant
Licensee purchased and received the license for the commercialization and exploitation of Stendra and acquired the current Stendra product and sample inventories as of September 30, 2016 that were owned by Licensor. The License Agreement gives Licensee the right to sell Stendra in the U.S and its territories, Canada, South America, and India. This also includes for the trademark assignment and the use of the trademarks associated with the Product and the Licensor technology.
License Property
Stendra® is a PDE5 inhibitor pharmaceutical product indicated for the treatment of male erectile dysfunction.
Field of Use
The Field of Use is for the treatment of male erectile dysfunction.

IPSCIO Record ID: 245896

License Grant
Licensor grants an exclusive, even as to Licensor, sublicensable license under the Licensor Technology, to use, distribute, import, Promote, market, sell, offer for sale, and otherwise Commercialize Products in the Field in the Licensee Territory; and, make and have made Products in the Manufacturing Territory, where such Product is solely for use or sale in the Field in the Licensee Territory, and, to conduct certain Development activities on the Product in the Field solely in support of Regulatory Approval in the Licensee Territory; and, an exclusive, sublicensable license to use the Licensor Trademarks solely in connection with the
Commercialization of the Product in the Field in the Licensee Territory.
License Property
The Licensor has rights to a therapeutic drug known as STENDRA TM (avanafil).

Compound means the compound identified by the International NonProprietary Name avanafil and chemically known as (S)-4-(3-Chloro-4-methoxybenzylamino)-2-(2-hydroxymethylpyrrolidin-1-yl)-N-pyrimidin-2-ylmethyl-5-pyrimidinecarboxyamide, including any metabolites, polymorphs, salts, esters, free acid forms, free base forms, pro-drug forms, racemates and all optically active forms thereof.

Product means pharmaceutical compositions containing the Compound, including but not limited to that drug product known as STENDRA â„¢, in the form, formulation, and dosage strength(s) as defined in the NDA approved by the FDA as of the Effective Date and any other improvements, line extensions, delivery mechanisms, dosage strengths, formulations, or forms as may be approved in the future by the FDA or Health Canada that, in each case, contain a Compound.

Licensor Trademarks means the mark STENDRA.

Field of Use
The Field means the treatment of any urological disease or condition in humans, including male erectile dysfunction.

STENDRA is now the only FDA-approved erectile dysfunction (ED) medication indicated to be taken as early as approximately 15 minutes before sexual activity.

IPSCIO Record ID: 367114

License Grant
Licensor hereby grants Licensee the exclusive right and license to practice the Licensor's Patents and the Licensor Know-How to develop, have developed, make, have made, use, import, export, offer for sale, sell and have sold Licensed Products for the Indications anywhere in the world as well as further license the Product and/or the Licensed Products for the Indications for one or more of the Indications provided such licensing shall not affect the right of Autotelic under this agreement.

Licensor will out-license its product comprising of the intra-nasal drug and delivery system related to, but not limited to, nasal apomorphine (the Product) to Licensee. Licensee will license AL-101, intranasal apomorphine, from Licensor.

License Property
AL-101, intranasal apomorphine, has a favorable safety and efficacy profile and is phase 3 ready with six clinical trials completed and over 200 patients (2,200 doses) treated. Apomorphine is a direct-acting dopamine agonist with strong D1 and D2 dopamine receptor–stimulating properties that is administered by a parenteral route (intravenously, rectally, subcutaneously, sublingually, or intranasally). It has similar efficacy to levodopa with a substantially more rapid time to onset.

PATENTS
Application No. 63235101, Intranasal Apomorphine – Methods of Use

Application No. 63243175, Fast Acting Treatment of Parkinson with Rapid Delivery of Drug to Brainstem

Application No. 63243177, Combination Therapy for Erectile Dysfunction

INDICATIONS
Parkinson’s Disease
Erectile dysfunction
Female sexual dysfunction (also called hypoactive sexual desire disorder)

“Indications” shall mean Parkinson’s Disease (PD), erectile dysfunction (ED), female sexual dysfunction (FSD – also called hypoactive sexual desire disorder (HSDD)) or any other indications related to the Product that are or may be identified in the future.

Field of Use
Field of use is for the treatment of Parkinson Disease (PD) and Erectile Dysfunction (ED), especially phosphodiesterase 5 (PDE5) non-responders. AL-101 will also be developed as a new drug against Female Sexual Dysfunction (FSD), including Hypoactive Sexual Desire Disorder (HSDD).

PDE5 is an enzyme in the walls of blood vessels. It affects blood flow and how cells signal within the body. PDE5 inhibitors block the PDE5 enzyme to prevent it from working. This inhibition relaxes the blood vessels and increases blood flow.

Hypoactive Sexual Desire Disorder — also called HSDD — is when you're not interested in sex (have no sex drive or a low sex drive), and it bothers you. It's one of the most common sexual problems that people have.

IPSCIO Record ID: 4898

License Grant
The Company entered into a royalty agreement with the Licensor, an individual, for the intellectual rights to patent, develop, manufacture, and market the LLPGE-1 for the treatment of male erectile dysfunction, impotency and sexual enhancement.
License Property
U.S. Patent 573408 PGE-1 containing lyophilized liposomes for use in the treatment of erectile dysfunction.
Field of Use
The field of use relates to the medical industry.  The Licensee is a development stage biopharmaceutical company whose corporate objective is to utilize medically researched and developed drug substances for sexual dysfunction, determine the ability of these substances to be delivered effectively and determine the potential market for such products.

IPSCIO Record ID: 28038

License Grant
The two pharmaceutical companies entered into a License and Commercialization Agreement that granted the exclusive right to commercialize licensor's pharmaceutical product Stendratm (avanafil) for the treatment of any urological disease or condition in humans, including male erectile dysfunction in the United States and Canada and their respective territories.
Field of Use
Avanafil (tradename Stendra) is a phosphodiesterase 5 (PDE5) inhibitor for the treatment of erectile dysfunction (ED).
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.